Tango Therapeutics, Inc. (TNGX)
Largest Insider Buys in Sector
TNGX Stock Price History Chart
TNGX Stock Performance
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with …
Insider Activity of Tango Therapeutics, Inc.
Over the last 12 months, insiders at Tango Therapeutics, Inc. have bought $74,000 and sold $59.02M worth of Tango Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Tango Therapeutics, Inc. have bought $4.58M and sold $20.44M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rothenberg Mace (director) — $74,000.
The last purchase of 10,000 shares for transaction amount of $37,800 was made by Rothenberg Mace (director) on 2024‑11‑18.
List of Insider Buy and Sell Transactions, Tango Therapeutics, Inc.
| 2024-11-18 | director | 10,000 0.0098% | $3.78 | $37,800 | -4.76% | |||
| 2024-11-14 | director | 10,000 0.0088% | $3.62 | $36,200 | 0.00% | |||
| 2024-11-07 | Sale | 10 percent owner | 1.21M 1.1237% | $2.94 | $3.54M | +21.20% | ||
| 2024-11-06 | Sale | 10 percent owner | 1.49M 1.3103% | $3.28 | $4.9M | +4.63% | ||
| 2024-11-06 | Sale | See remarks | 3.08M 2.5882% | $3.14 | $9.67M | +4.63% | ||
| 2024-10-25 | Sale | See remarks. | 633,000 0.6113% | $6.87 | $4.35M | 0.00% | ||
| 2024-10-22 | Sale | See remarks | 250,000 0.2383% | $6.78 | $1.7M | 0.00% | ||
| 2024-10-21 | Sale | See remarks | 625,000 0.5752% | $7.05 | $4.41M | -50.77% | ||
| 2024-09-13 | Sale | 10 percent owner | 67,400 0.0631% | $10.53 | $709,756 | -56.05% | ||
| 2024-09-05 | Sale | 10 percent owner | 75,000 0.0693% | $11.56 | $867,135 | -53.42% | ||
| 2024-08-30 | Sale | 10 percent owner | 175,000 0.1601% | $11.60 | $2.03M | -50.51% | ||
| 2024-08-27 | Sale | 10 percent owner | 25,000 0.0236% | $11.55 | $288,665 | -42.54% | ||
| 2024-08-19 | Sale | 10 percent owner | 150,000 0.1323% | $10.09 | $1.51M | -35.77% | ||
| 2024-08-16 | Sale | 10 percent owner | 135,000 0.1454% | $9.79 | $1.32M | +2.01% | ||
| 2024-08-01 | Sale | 10 percent owner | 40,000 0.0388% | $9.80 | $392,000 | -26.14% | ||
| 2024-07-31 | Sale | 10 percent owner | 100,000 0.0958% | $9.93 | $993,380 | 0.00% | ||
| 2024-07-30 | Sale | 10 percent owner | 95,000 0.0898% | $9.80 | $931,114 | 0.00% | ||
| 2024-07-26 | Sale | 10 percent owner | 50,000 0.0472% | $9.84 | $491,950 | -28.31% | ||
| 2024-07-25 | Sale | 10 percent owner | 100,599 0.0943% | $9.87 | $992,771 | -28.98% | ||
| 2024-07-24 | Sale | 10 percent owner | 200,000 0.1854% | $9.82 | $1.96M | 0.00% |
Insider Historical Profitability
| Rothenberg Mace | director | 31250 0.0291% | $3.04 | 2 | 0 | |
| Boxer Capital, LLC | 8198642 7.6325% | $3.04 | 3 | 1 | ||
| Davis Aaron I. | director | 7123642 6.6317% | $3.04 | 3 | 0 | +36.98% |
| LEWIS JOSEPH | director | 7053642 6.5665% | $3.04 | 3 | 0 | +39.17% |
| BCTG Holdings, LLC | 10 percent owner | 4488450 4.1785% | $3.04 | 1 | 1 | +7.42% |
Institutional Investor Ownership
| Trv Gp Iv Llc | $152.46M | 17.97 | 19.2M | -0.84% | -$1.29M | 73.88 | |
| Ecor1 Capital Llc | $105.85M | 12.48 | 13.33M | 0% | +$0 | 0.74 | |
| Fidelity Investments | $75.36M | 8.88 | 9.49M | -3.02% | -$2.35M | 0.01 | |
| Boxer Capital, LLC | $65.1M | 7.67 | 8.2M | 0% | +$0 | 1.33 | |
| Nextech Invest | $43.94M | 5.18 | 5.53M | 0% | +$0 | 7.16 |